HC Wainwright & Co. Maintains Buy on Jade Biosciences, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 66.0%

Neg 0% Neu 0% Pos 66%

HC Wainwright & Co. analyst Arthur He maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and raises the price target from $45 to $55.